site logo

CAS 461432-23-5 Dapagliflozin Intermediate

CAS 461432-23-5 Dapagliflozin Intermediate

Port: Shanghai, China
Production Capacity: 100 Kilogram/Kilograms Per Week
Payment Terms: T/T, D/P, Western Union, Paypal
Powder: Yes
Certification: GMP, HSE, ISO 9001, USP, BP
State: Solid
Purity: >99%
Name: Dapagliflozin
CAS: 461432-23-5

Other Names Dapagliflozin Intermediate
CAS No 461432-23-5
Molecular formula C15H14BrClO
Molecular weight 325.6281
EINECS no. 636-921-5
Grade Pharmaceutical grade

What is Dapagliflozin?

Dapagliflozin is a new type of antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. It was approved by the European Medicines Agency (EMA) on November 12, 2012 and is the first to be approved. SGLT2 inhibitors for the treatment of type 2 diabetes are important candidates for the treatment of diabetes. They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Function and Application

Dapagliflozin A sodium-glucose transporter 2 inhibitor,Pharmaceutical raw materials.